Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2023; 20(13):1705-1710. doi:10.7150/ijms.88720 This issue Cite

Research Paper

Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus

Yen-Po Yao1,2, Po-Jen Yang3,4, Chia-Yi Lee1,5,6, Jing-Yang Huang1,7, Shun-Fa Yang1,7,✉, Hung-Yu Lin1,2,8,9,✉

1. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
2. Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan.
3. Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
4. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
5. Department of Ophthalmology, Nobel Eye Institute, Taipei, Taiwan.
6. Department of Ophthalmology, Jen-Ai Hospital Dali Branch, Taichung, Taiwan.
7. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
8. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
9. Department of Optometry, Chung Shan Medical University, Taichung, Taiwan.

✉ Corresponding authors: Shun-Fa Yang, Ph.D. or Hung-Yu Lin, MD, Ph.D., Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Tel: +886-4-24739595 ext. 34253; Fax: +886-4-24723229; E-mail: ysfedu.tw (Shun-Fa Yang); E-mail: More

Citation:
Yao YP, Yang PJ, Lee CY, Huang JY, Yang SF, Lin HY. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. Int J Med Sci 2023; 20(13):1705-1710. doi:10.7150/ijms.88720. https://www.medsci.org/v20p1705.htm
Other styles

File import instruction

Abstract

Graphic abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have protective effects against various systemic diseases and neoplasms. This retrospective cohort study evaluated the severity of dry eye disease (DED) in patients with type 2 diabetes mellitus (T2DM) who were treated with SGLT2 inhibitors. Data were obtained from the National Health Insurance Research Database of Taiwan. Patients with T2DM who were treated with SGLT2 inhibitors were assigned to the SGLT2 group. Each patient in the SGLT2 group was matched to two individuals with T2DM who had not used SGLT2 inhibitors, constituting the control group. The primary outcomes were the development of DED and severe DED. A diagnosis of severe DED was indicated by the usage of cyclosporine. Cox proportional hazard regression was applied to yield adjusted hazard ratios (aHR) and 95% confidence intervals (CIs). In the SGLT2 group, 1864 new DED events and 147 severe DED events were recorded. Conversely, 4367 new DED events and 392 severe DED events were recorded in the control group. The incidence (aHR: 0.858, 95% CI: 0.811-0.908, p = 0.0010) and severity (aHR: 0.652, 95% CI: 0.481-0.777, p = 0.0006) of DED were significantly lower in the SGLT2 group than the control group after adjusting for multiple covariates. In subgroup analyses, the incidence and severity of DED were significantly lower in patients younger than 60 years old who were treated with SGLT2 inhibitors than in their older counterparts (p = 0.0008 and 0.0011, respectively). In conclusion, utilization of SGLT2 inhibitors in the T2DM population could reduce both the incidence and severity of DED.

Keywords: dry eye disease, SGLT2 inhibitors, epidemiology, diabetes mellitus, severity

Citation styles

APA
Yao, Y.P., Yang, P.J., Lee, C.Y., Huang, J.Y., Yang, S.F., Lin, H.Y. (2023). Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. International Journal of Medical Sciences, 20(13), 1705-1710. https://doi.org/10.7150/ijms.88720.

ACS
Yao, Y.P.; Yang, P.J.; Lee, C.Y.; Huang, J.Y.; Yang, S.F.; Lin, H.Y. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. Int. J. Med. Sci. 2023, 20 (13), 1705-1710. DOI: 10.7150/ijms.88720.

NLM
Yao YP, Yang PJ, Lee CY, Huang JY, Yang SF, Lin HY. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. Int J Med Sci 2023; 20(13):1705-1710. doi:10.7150/ijms.88720. https://www.medsci.org/v20p1705.htm

CSE
Yao YP, Yang PJ, Lee CY, Huang JY, Yang SF, Lin HY. 2023. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. Int J Med Sci. 20(13):1705-1710.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use